SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes
Conditions: Type2diabetes; PreDiabetes; Renal Failure Interventions: Drug: Dapagliflozin (Forxiga ®); Drug: Placebo matching Dapaglifolzin; Behavioral: Lifestyle Intervention Sponsors: University Hospital Tuebingen; German Federal Ministry of Education and Research; German Center for Diabetes Research; AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: AstraZeneca | Dapagliflozin | Diabetes | Education | Endocrinology | Forxiga | Germany Health | Hospitals | Renal Failure | Research | SGLT2 Inhibitors | Universities & Medical Training